Itriglumide
Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC50 of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC50 of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity[1].
Product Specifications
CAS Number
201605-51-8
Product Name Alternative
CR 2945
UNSPSC
12352005
Target
Cholecystokinin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/itriglumide.html
Smiles
O=C(C1=C(C(C)=CC(C)=C1)NC(C[C@@H](C2=CC=CC3=CC=CC=C23)CC(O)=O)=O)N4CCC5(CCCC5)CC4
Molecular Formula
C33H38N2O4
Molecular Weight
526.67
References & Citations
[1]Makovec F, et al. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK (B) receptor antagonist. Eur J Pharmacol. 1999 Mar 12;369 (1) :81-90.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CCKBR
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
